(Bloomberg) -- Novo Nordisk A/S said its diabetes treatment Tresiba showed “significantly improved” blood sugar control and lower rates of hypoglycemia compared with insulin glargine U300 in real-world evidence study.
- Novo says that adults with type 2 diabetes who were treated with Tresiba saw a significant reduction in HbA1c and a 30 percent lower rate of hypoglycemic episodes after starting basal insulin.
- The findings will be presented on Monday at an American Diabetes Association event in Orlando, Novo said
- Link to the full statement
To contact the reporter on this story: Tasneem Hanfi Brögger in Copenhagen at tbrogger@bloomberg.net
To contact the editor responsible for this story: Tasneem Hanfi Brögger at tbrogger@bloomberg.net
©2018 Bloomberg L.P.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
